amfAR, The Foundation for AIDS Research, is one of the world’s leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of sound AIDS related public policy. Since 1985, amfAR has invested more than $3888 million in its programs and has awarded more than 3,300 grants to research teams worldwide.

Among many accomplishments, amfAR supported early studies that led to the development of four of the six main classes of anti-HIV drugs that allow people living with HIV/AIDS to live longer, healthier lives, and amfAR pioneered the research that led to the use of antiretroviral drugs to prevent mother-to-child transmission of HIV.

Today amfAR’s research focus is on the search for a cure for HIV/ AIDS, primarily through its support of leading scientists working collaboratively within the amfAR Research Consortium on HIV Eradication (ARCHE).


Bio-Rad Laboratories, Inc. designs, manufactures, and distributes a broad range of innovative tools and services to the life science research and clinical diagnostics markets. Founded in 1952, Bio-Rad has a global team of more than 7,750 employees and serves more than 100,000 research and industry customers worldwide through the company’s global network of operations. Throughout its existence, Bio-Rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, and medical diagnostics.

The Life Science Group develops, manufactures, and markets a wide range products used for research in functional genomics, proteomics, and food safety. The group ranks among the top five life science companies worldwide, and maintains a solid reputation for quality, innovation, and a longstanding focus on the success of its customers. Bio-Rad’s life science technologies include electrophoresis, imaging, multiplex immunoassay, chromatography, microbiology, bioinformatics, protein function analysis, transfection, amplification, real-time and droplet digital PCR.

The Clinical Diagnostics Group develops, manufactures, sells, and supports a large portfolio of products for laboratory diagnostics. Bio-Rad is a leading specialty diagnostics company and its products are recognized as the gold standard for diabetes monitoring and quality control (QC) systems. The company is also well known for its blood virus testing and detection, blood typing, and autoimmune and genetic disorders testing.


Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, serious respiratory and cardiovascular conditions, cancer and inflammation. Our portfolio of 16 marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill.


Sangamo BioSciences, Inc. is a clinical-stage biotechnology company, based in the San Francisco Bay Area, focused on Engineering Genetic CuresTM for monogenic and infectious diseases. Sangamo is deploying its proprietary zinc finger DNA-binding protein (ZFP) technology platform in therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS (SB-728-T) and NGFAAV for Alzheimer’s disease (CERE-110). Sangamo’s other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia A and B, Huntington’s disease, and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation.



RainDance Technologies is making complex genetics simple. The company’s ultra-sensitive genomic tools enable better research of novel non-invasive Fluid Biopsy™ applications that should result in more accurate, reliable, cost-effective and early detection of cancer, inherited and infectious diseases. Major research institutions and laboratories around the world rely on RainDance systems’ performance. Based in Billerica, Massachusetts, the company supports customers using RainDrop® Digital PCR and ThunderStorm® Targeted Next-Generation Sequencing Systems through its international sales and service operations as well as a global network of distributors and commercial service providers.


Sigma-Aldrich and Miltenyi Biotech




Conference registration and travel considerations for Community Advisory Board members from the Martin Delaney Collaboratories of defeatHIV, DARE and CARE have been provided by the generous underwriting support from Gilead Sciences and Sangamo BioSciences, Inc.